Journal of Bioequivalence & Bioavailability (JBB)

The Journal of Bioequivalence & Bioavailability (JBB) is an academic journal that encompasses a wide range of current research on FDA Bioequivalence, Bioequivalence antipsychotics, Bioequivalence anticancers, Bioequivalence antidiuretics, Bioequivalence antipsychotics, BA/BE Studies, Biosimilars, Advances in Bioavailability and offers a promising platform for the authors to make their valuable contributions towards the journal. Journal of Bioequivalence & Bioavailability is the best open access journal that aims to publish most complete and reliable source of information on the discoveries and advanced developments in this field in the form of original articles, review articles, case reports, short communications, etc. and provide free online access to it without any restrictions or any other subscriptions to researchers worldwide. Journal of Bioequivalence & Bioavailability is one of the best Open Access journals of Scholarly publishing. The Bioequivalence Peer Reviewed Journal is proficiently supported by universally prominent Editorial Board members. Bioequivalence journal impact factor is mainly calculated based on the number of articles that undergo single blind peer review process by competent Editorial Board so as to ensure excellence, essence of the work and number of citations received for the same published articles.

Journal of Bioequivalence & Bioavailability (JBB) is :-

• International, Peer-Reviewed, Open Access, Refereed, Bioequivalence, Bioavailability, Pharmacokinetics, Pharmaceutical Sciences, Clinical Pharmacology, Biosimilars, Drug Development , Online , Bi-Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN E-ISSN: 0975-0851, Established: 2009, Impact Factor: 6.89
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE